1-2 of 2
Modupe Idowu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Clinical Trials & Observations
Santosh L. Saraf, Robert Hagar, Modupe Idowu, Ifeyinwa Osunkwo, Kimberly Cruz, Frans A. Kuypers, R. Clark Brown, James Geib, Maria Ribadeneira, Patricia Schroeder, Eric Wu, Sanjeev Forsyth, Patrick F. Kelly, Theodosia A. Kalfa, Marilyn J. Telen
Journal: Blood Advances
Blood Adv (2024) 8 (16): 4459–4475.
https://doi.org/10.1182/bloodadvances.2023012467
Published: 2024
Includes: Supplemental data
Journal Articles

Elevated ecto-5′-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease

Hong Liu, Morayo Adebiyi, Rong Rong Liu, Anren Song, Jeanne Manalo, Yuan Edward Wen, Alexander Q. Wen, Tingting Weng, Junsuk Ko, Modupe Idowu, Rodney E. Kellems, Holger K. Eltzschig, Michael R. Blackburn, Harinder S. Juneja, Yang Xia
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1957–1968.
https://doi.org/10.1182/bloodadvances.2018015784
Published: 2018
Includes: Supplemental data